MIA2 and esophageal squamous cell carcinoma: We found that patients with ESCC whose samples exhibited positive MIA, MIA2, and TANGO immunostaining had significantly shorter disease-free survival intervals, compared to patients with negative expression (P < 0.0001, P = 0.0135, and P = 0.0131, respectively; Figure 6A–6C).